BioNxt Solutions Prepares for Human Bioequivalence Study For MS
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Graid Technology Announces Strategic License Agreement With Intel Corporation to Accelerate RAID Innovation14.10.2025 18:00:00 CEST | Press release
SANTA CLARA, CALIFORNIA / ACCESS Newswire / October 14, 2025 / Graid Technology announced an agreement with Intel Corporation to enter into a license agreement granting Graid Technology the rights to develop, market, sell, and support Intel® Virtual RAID on CPU (Intel® VROC) globally. This strategic agreement is expected to accelerate innovation in the enterprise RAID market and deliver transformative outcomes for data center customers worldwide.Graid Technology and Intel Announce Strategic License Agreement In today's digital economy, data is the most valuable asset for every organization, and ensuring it is both resilient and readily available is critical to unlocking its full value. Through this agreement, Graid Technology will combine the proven enterprise performance of Intel® VROC with the breakthrough innovation of its own SupremeRAID™ portfolio, the industry's first GPU-based RAID architecture for high-performance workloads such as AI and HPC. By bringing together CPU-based and
GA-ASI and Hanwha Finalize Deal To Produce Gray Eagle(R) STOL UAS14.10.2025 17:00:00 CEST | Press release
Partnership Will Enable Cost Savings By Manufacturing Unique and Flexible UAS Platform in South Korea SAN DIEGO, CA / ACCESS Newswire / October 14, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and South Korea industry leader Hanwha Aerospace signed an agreement on October 14 to partner in development of the Gray Eagle® Short Takeoff and Landing (GE STOL) unmanned aircraft system (UAS). This landmark agreement marks the beginning of a new phase in U.S.-Korea defense cooperation, extending beyond traditional alliance structures to deliver next-generation, runway-independent UAS solutions that maximize commanders' options in the face of evolving mission demands. The deal marks the beginning of a co-development and co-production program between GA-ASI and Hanwha, with work set to begin immediately. The GE STOL will be offered to a worldwide customer base, including South Korea Ministry of Defense and the United States War Department. Under the agreement, the two companies wil
Polaris Renewable Energy Announces New Credit Facility, Executive Enhancements & Q3-25 Earnings Conference Call14.10.2025 13:50:00 CEST | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 14, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce that it has entered into a US$3.5 Million Working Capital & a US$10.0 Million Letter of Credit Facility (the Facility) with the Canadian Imperial Bank of Commerce (CIBC) and the Export Development Canada (EDC). The Facility will enhance Polaris' liquidity as it continues to work towards growing its current footprint in Latin America and the Caribbean. CIBC has been the lead Banker for Polaris in Canada since 2015, while the EDC has also supported the Company in the past with similar facilities. The Company is also pleased to announce changes to its Named Executive Officers effective October 9th, as follows: Anton Jelic, CFO of the Company since December 2018 will be moving to a new role as Chief Administrative Officer to focus on Polaris' continuing growth in such key areas as IT, AI, Human Resources, Risk and continuing to strengthen Corpo
From Manual to Autonomous: Agentic CMS Automates Governance, Compliance, and Content Maintenance14.10.2025 09:00:00 CEST | Press release
Kontent.ai unveils the first CMS built for the AI era - automating governance, compliance, translations, and large-scale updates so teams can focus on creativity and growth. BRNO, CZ / ACCESS Newswire / October 14, 2025 / Across industries, marketing and content teams are being asked to achieve more with fewer resources. Yet expectations for faster publishing, more content and consistency keep rising.AI Agent reviewing thousands of content items AI Agent reviewing entire content repository for specific terms Under that pressure, generative AI has burst onto the scene, reshaping how content is created and discovered. Large language models (LLMs) and generative search experiences are redefining what customers see, hear, and believe about brands. But without structure and governance, AI can easily create more noise than value by diluting tone and introducing compliance risks. Agentic CMS was created to solve this tension. As the world's first agentic content management system, Kontent.ai'
Padcom and General Holdings Sign Term Sheet for USD 55 Million Structured Investment13.10.2025 15:00:00 CEST | Press release
RUSSELL, MB AND DUBAI, UAE, NY / ACCESS Newswire / October 13, 2025 / Potash and Agri Development Corporation of Manitoba Ltd. ("Padcom") and General Holdings Limited ("General Holdings"), a Dubai International Financial Centre (DIFC)-based private investment platform, are pleased to announce the signing of a US$55 million structured investment term sheet. The transaction outlines Padcom's next stage of expansion and General Holdings' continued focus on sustainable industrial and resource-linked investments. The transaction was originated by North Mountain Capital, which introduced the opportunity to General Holdings. Under the term sheet, General Holdings proposes to invest US$18.25 million as a Senior Secured Loan (Tranche 1) and US$36.75 million as Series A Preferred Equity (Tranche 2), with full warrant coverage. The proceeds will be used to expand Padcom's production capacity to 250,000 tonnes per annum of potash and related products, with an intended public listing targeted withi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom